Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-10 8:46 pm Purchase | 2025-02-06 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS, L.P. | 11,560,350 40.200% | 6,481,034 (+127.60%) | Filing History |
| 2025-01-28 8:07 pm Purchase | 2025-01-27 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 57,848,357 24.500% | 15,789,474 (+37.54%) | Filing History |
| 2024-11-21 8:05 pm Purchase | 2024-11-19 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 42,058,883 19.100% | 75,000 (+0.18%) | Filing History |
| 2024-11-14 5:09 pm Purchase | 2024-09-30 | 13G | Serina Therapeutics Inc SER | BROADWOOD PARTNERS, L.P. | 187,871 2.100% | 187,871 (New Position) | Filing History |
| 2024-04-15 7:26 pm Purchase | 2024-04-11 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS, L.P. | 5,079,316 37.600% | 5,079,316 (New Position) | Filing History |
| 2024-02-08 6:57 pm Purchase | 2024-02-06 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 41,983,883 22.200% | 6,756,610 (+19.18%) | Filing History |
| 2024-01-10 5:23 pm Purchase | 2024-01-04 | 13D | STAAR Surgical Company STAA | BROADWOOD PARTNERS, L.P. | 10,794,330 22.100% | 665,586 (+6.57%) | Filing History |
| 2023-11-15 5:27 pm Purchase | 2023-11-09 | 13D | STAAR Surgical Company STAA | BROADWOOD PARTNERS, L.P. | 10,128,744 20.700% | 633,121 (+6.67%) | Filing History |
| 2023-10-10 08:00 am Purchase | 2023-10-04 | 13D | STAAR Surgical Company STAA | BROADWOOD PARTNERS, L.P. | 9,495,623 19.600% | 877,716 (+10.18%) | Filing History |
| 2023-04-07 10:38 am Purchase | 2023-04-03 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS, L.P. | 2,856,559 33.300% | 1,345,914 (+89.10%) | Filing History |
| 2022-07-28 5:06 pm Purchase | 2022-07-21 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS, L.P. | 1,510,645 24.100% | 321,897 (+27.08%) | Filing History |
| 2022-04-15 5:21 pm Purchase | 2022-04-13 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS, L.P. | 1,188,748 19.990% | 296,969 (+33.30%) | Filing History |
| 2022-03-25 5:23 pm Purchase | 2022-03-10 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 35,227,273 20.700% | 980,106 (+2.86%) | Filing History |
| 2021-10-01 4:59 pm Sale | 2021-10-01 | 13D | STAAR Surgical Company STAA | BROADWOOD PARTNERS, L.P. | 8,617,907 18.200% | -408,350 (-4.52%) | Filing History |
| 2021-09-24 4:40 pm Unchanged | 2021-09-23 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS, L.P. | 891,780 19.300% | 0 (Unchanged) | Filing History |
| 2021-06-15 8:46 pm Sale | 2021-06-14 | 13D | STAAR Surgical Company STAA | BROADWOOD PARTNERS, L.P. | 9,026,257 19.200% | -443,734 (-4.69%) | Filing History |
| 2021-04-05 5:12 pm Sale | 2021-04-01 | 13D | STAAR Surgical Company STAA | BROADWOOD PARTNERS, L.P. | 9,469,991 20.300% | -455,931 (-4.59%) | Filing History |
| 2021-03-16 5:04 pm Purchase | 2021-03-11 | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS, L.P. | 34,247,167 21.200% | 34,247,167 (New Position) | Filing History |
| 2021-02-09 5:10 pm Purchase | 2021-02-05 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS, L.P. | 891,780 20.100% | 30,000 (+3.48%) | Filing History |
| 2021-01-28 5:25 pm Sale | 2021-01-26 | 13D | STAAR Surgical Company STAA | BROADWOOD PARTNERS, L.P. | 9,925,922 21.500% | -895,326 (-8.27%) | Filing History |